The SPARKLE registry: a multicenter, multinational, noninterventional, prospective cohort registry study in patients with alpha-mannosidosis

CURRENT STATUS: UNDER REVIEW

Julia Hennermann  
Johannes Gutenberg-Universitat Mainz Universitatsmedizin Zentrum fur Kinder- und Jugendmedizin  
Corresponding Author

Nathalie Guffon  
Hopital Femme Mere Enfant

Federica Cattaneo  
Chiesi Farmaceutici Spa

Ferdinando Ceravolo  
Chiesi Farmaceutici Spa

Line Borgwardt  
Rigshospitalet

Allan M. Lund  
Rigshospitalet

Mercedes Gil-Campos  
Hospital General Universitario Reina Sofia

Anna Tylki-Szymanska  
Instytut Pomnik -Centrum Zdrowia Dziecka

Nicole M. Muschol  
Universitatsklinikum Hamburg-Eppendorf

DOI:  
10.21203/rs.2.19376/v1

SUBJECT AREAS

Internal Medicine

KEYWORDS
Alpha-mannosidosis, Recombinant alpha-mannosidase, Velmanase alfa, Patient registry, Enzyme-replacement therapy
Abstract

Background

Alpha-mannosidosis is a lysosomal storage disorder caused by reduced enzymatic activity of alpha-mannosidase. Intracellular accumulation of mannose-rich oligosaccharides leads to a continuum of various heterogeneous clinical symptoms. Velmanase alfa (Lamzede®) is a human recombinant alpha-mannosidase approved in Europe in 2018 as the first enzyme replacement therapy for the treatment of non-neurologic manifestations in patients with mild-to-moderate alpha-mannosidosis. SPARKLE is an alpha-mannosidosis registry study intended to obtain long-term safety and effectiveness data on the use of velmanase alfa during routine clinical care in patients with alpha-mannosidosis and is a post-approval commitment to European marketing authorization. In addition, SPARKLE will expand the current understanding of alpha-mannosidosis by collecting data on the clinical manifestations, progression, and natural history of the disease in treated and untreated patients, respectively.

Results

SPARKLE is a post-authorization safety and efficacy registry designed as a multicenter, multinational, noninterventional, prospective cohort study of patients with alpha-mannosidosis, starting in 2020. Patients will be followed for up to 15 years. Safety and effectiveness outcomes under routine clinical care will be evaluated. The primary safety outcomes are the rate of adverse events (anti-velmanase alfa-immunoglobulin G antibody development, infusion-related reactions, and hypersensitivity). Secondary safety outcomes include the evaluation of medical events, change in vital signs, laboratory tests, physical examination, and electrocardiogram results. The primary effectiveness outcome is a global treatment response rate, evaluated as the individual aggregate of single endpoints from pharmacodynamic, functional, and quality of life effectiveness outcomes; secondary effectiveness outcomes are to characterize the population of patients with alpha-mannosidosis with regard to clinical manifestation, progression, and natural history of the disease. Any patient in the European Union with a diagnosis of alpha-mannosidosis who is willing to participate will likely be eligible for inclusion in the registry. Publications to disseminate scientific insights from the registry are planned.
Conclusion

This study will provide real-world data on the long-term safety and effectiveness of velmanase alfa in patients with alpha-mannosidosis during routine clinical care and increase the understanding of the natural course, clinical manifestations, and progression of this ultra-rare disease.

Background

Alpha-mannosidosis (OMIM 248500) is an ultra-rare monogenic disorder caused by alpha-mannosidase deficiency (Enzyme Commission number: 3.2.1.24) and has an estimated prevalence of 1:500,000–1:1,000,000 live births [1]. It is an autosomal recessive, lysosomal-storage disease resulting from mutations in the MAN2B1 gene, located on chromosome 19 (19 p13.2-q12) [2]. As alpha-mannosidase is a lysosomal enzyme involved in glycoprotein catabolism, reduced activity results in impaired degradation of glycoproteins and leads to an accumulation of mannose-rich oligosaccharides in various tissues [3].

Intracellular accumulation of mannose-rich oligosaccharides leads to different clinical symptoms, including hearing impairment, intellectual disabilities, impairment of motor function and speech development, recurrent infections, immunodeficiency, skeletal abnormalities, destructive polyarthropathy, muscular weakness, ataxia, and psychiatric disease [1]. Alpha-mannosidosis presents in a continuum of clinical symptoms and is a heterogeneous disorder due to the varied manifestations and their different severity, as well as various rates of progression in individual patients [4]. In the majority of patients, the disease is clinically recognized in the first decade of life, progression is slow, and ataxia develops between the ages of 20 to 30 years [1].

Long-term enzyme replacement therapy (ERT) is a therapeutic option for alpha-mannosidosis [5] and velmanase alfa is the first human recombinant form of alpha-mannosidase available for ERT. To date, velmanase alfa (Lamzede®, Chiesi Farmaceutici S.p.A., Parma, Italy) is the only authorized treatment for alpha-mannosidosis in Europe; it is approved for the treatment of non-neurologic manifestations in patients with mild-to-moderate alpha-mannosidosis [6]. Velmanase alfa targets the underlying cause of the disease by breaking down mannose-rich oligosaccharides that would otherwise accumulate in the lysosome [7]. The velmanase alfa molecule has an identical structure to naturally occurring alpha-
mannosidase and is approved for use at 1 mg/kg body weight once weekly as an intravenous infusion [6]. After infusion, velmanase alfa is taken up by cells and transported to the lysosomes, where it replaces the patient’s defective enzyme and thus reduces levels of accumulated oligosaccharides [7]. Velmanase alfa also has Orphan Drug designation in the United States and Europe.

In clinical trials, patients with alpha-mannosidosis treated with velmanase alfa achieved improvements in biomarkers, motor function, pulmonary function, immunologic profile, and quality of life (QoL) [3, 5, 8]. Importantly, a novel global treatment-response model composed of pharmacodynamic, functional, and QoL outcomes was applied post hoc to data from the pivotal, randomized controlled trial (RCT) of velmanase alfa in patients with alpha-mannosidosis (NCT01681953) and the longer-term integrated data from all patients in the clinical development program. A global response required positive responses in at least two outcome domains of the model [3]. In the pivotal RCT, 13 of 15 patients (86.7%) treated with velmanase alfa achieved a global response compared with three of 10 patients (30.0%) who received placebo [3]. Similarly, in the integrated data set, 29 of 33 treated patients (87.9%) were global responders (100% of pediatric patients [n = 19] and 71% of adults [n = 10]) [3].

SPARKLE is an alpha-mannosidosis registry study intended to obtain long-term safety and effectiveness data on the use of velmanase alfa during routine clinical care in patients with alpha-mannosidosis and is a post-approval commitment to marketing authorization in Europe. In addition, SPARKLE will expand the current understanding of alpha-mannosidosis by collecting data on the clinical manifestation, progression, and natural history of the disease.

Methods
Study design

SPARKLE is a post-authorization safety and efficacy registry in Europe, designed as a multicenter, multinational, noninterventional, prospective cohort study of patients with alpha-mannosidosis (Fig. 1). The study will start in 2020 with an indefinite recruitment period. Patients will be followed for up to 15 years after inclusion. The end of the study is defined as the last visit of the last patient in the study. The study will be conducted under conditions of routine clinical practice, according to the
treating physician, without mandatory registry assessments. Patients are eligible for the study irrespective of treatment (velmanase alfa, hematopoietic stem cell transplantation or any biologic substance received as part of a clinical trial during participation in the registry).

The study will be conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice, Good Pharmacovigilance Practice, and all other applicable laws and regulations. The study will also be conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.

Patient population

Any patient in the European Union with a genetic confirmed diagnosis of alpha-mannosidosis who is willing to participate will be eligible for inclusion. Inclusion criteria are limited to a signed and dated informed consent form, including agreement to permit the Investigator to enter assessment data in the registry that has been recorded prior to inclusion in the registry, which has been obtained from the patient’s medical record. The inclusion form is signed by the patient, parents or a legally acceptable representative according to local regulation. There are no exclusion criteria.

Populations for analysis include a velmanase alfa and a no-velmanase alfa safety and efficacy analysis set. The velmanase alfa safety analysis set includes all patients in the registry who have, at some time, received any study drug treatment with a minimum individual follow-up of ≥1 month after the last dose. The velmanase alfa efficacy analysis set consists of patients in the same safety analysis set with efficacy evaluations during velmanase alfa treatment and for 12 months thereafter. The no-velmanase alfa safety analysis set includes patients only for the time when they are not, and have not within 1 month, been taking velmanase alfa. The no-velmanase alfa efficacy analysis set includes patients only for the time when they are not, and have not within 12 months, been taking velmanase alfa.

Baseline and demographic variables

At the registry baseline visit (first visit after inclusion), it is suggested that the following information will be reported in the electronic Case Report Form (eCRF): demographics (ethnicity, age, gender), medical and disease history, concomitant illnesses, previous and concomitant medications and
medical procedures, physical examination (including the ability to perform the endurance test and a hearing test), vital signs, and anthropometric measurements. For patients treated with velmanase alfa, the baseline data would be taken from the time treatment was initiated in order to provide a baseline for safety and effectiveness evaluations. Therefore, it is recommended to repeat a treatment baseline visit, if in accordance with routine clinical practice, in patients starting velmanase alfa treatment at any point during participation in the registry.

Safety variables

The primary safety outcomes of interest are rates of adverse events (AEs), with identified risks being anti-velmanase alfa-immunoglobulin G antibody (ADA), infusion-related reactions, and hypersensitivity (Table 1). Secondary safety outcomes include the evaluation of medical events (including but not limited to acute renal failure and loss of consciousness), change in vital signs (including systolic and diastolic blood pressure), laboratory tests (hematology and chemistry), physical examination, and electrocardiogram results. The suggested schedule of assessments is shown in Table 2, but assessments will be made based on the participating centers’ Standard Operating Procedures.

### Table 1

**Effectiveness and safety outcomes**

| Effectiveness Outcomes | Safety Outcomes |
|------------------------|-----------------|
| Laboratory assessments: | • AEs: serious and nonserious |
| • Serum oligosaccharides (µmol/L) | • ADRs: including serious and nonserious |
| • Serum IgG, IgA, and IgM | • AEs leading to treatment discontinuation and death |
| Functional assessments: | • Any identified risks including anti-VA-IgG antibody, infusion-related reactions, and hypersensitivity |
| • 3MSCT (steps/min) | • Any potential risk of acute renal failure, loss of consciousness, and medication errors |
| • 6MWT (m)¹ | • Vital signs: SBP, DBP, and pulse rate |
| • 2MWT (m)¹ | • Electrocardiogram |
| • FVC (L and % of predicted)¹ | • Laboratory tests (hematology and chemistry) |
| • Zarit Burden Interview | • Physical examination |
| • QoL questionnaire | Other: |
| • Behavior checklists for child and adult | • Psychotic events (rate) |

¹ In patients < 4 years of age, 3MSCT, 2MWT, and FVC% of predicted will be proposed upon the judgment of the physician.

**Abbreviations:** 2MWT 2-min walk test; 3MSCT 3-min stair-climb test; 6MWT 6-min walk test; ADR adverse drug reaction; AE adverse event; DBP diastolic blood pressure; EQ-5D-5L European Quality of Life, Five-Dimension, Five-Level Scale; FVC forced vital capacity; FVC% forced vital capacity, percent of predicted; Ig immunoglobulin; QoL quality of life; SBP systolic blood pressure; VA velmanase alfa.

### Table 2

**Suggested schedule**

| Procedure | Registry Inclusion Visit | Registry Baseline Visit | Unscheduled Follow-Up | Six-Month Follow-Up | Yearly Follow-Up Routine Clinical |
|-----------|-------------------------|-------------------------|-----------------------|---------------------|-----------------------------------|

7
|                              | (~--7 Days) | (Time 0) | Routine Clinical Visit¹ | Routine Clinical Visits² | Visits |
|------------------------------|------------|----------|-------------------------|--------------------------|--------|
| Administrative               |            |          |                         |                          |        |
| Informed consent form        | X          |          |                         |                          |        |
| Inclusion/exclusion criteria | X          |          |                         |                          |        |
| Medical and disease history  | X          |          |                         |                          |        |
| Preceding and concomitant    |            |          |                         |                          |        |
| medications, including VA    | X          |          |                         |                          |        |
| in hospital or home infusion |            |          |                         |                          |        |
| settings                      |            |          |                         |                          |        |
| Concomitant procedures       | X          |          |                         |                          |        |
| Physical examination         |            |          |                         |                          |        |
| (vital signs and anthropometric measurements, including rate of growth) | X | X | x | x | x |
| Demographics                 |            |          |                         |                          |        |
| Administration of medication |            |          |                         |                          |        |
| VA therapy, in hospital or   |            |          |                         |                          |        |
| home infusion setting         |            |          |                         |                          |        |
| Assessments                  |            |          |                         |                          |        |
| Standard hematological tests  |            |          |                         |                          |        |
| Laboratory chemistry         |            |          |                         |                          |        |
| Anti-VA-IgG antibody         |            |          |                         |                          |        |
| (ADA)                        |            |          |                         |                          |        |
| Oligosaccharides in serum    |            |          |                         |                          |        |
| Serum IgG, IgA, IgM          |            |          |                         |                          |        |
| 3MSCT, when applicable       |            |          |                         |                          |        |
| 6MWT, when applicable        |            |          |                         |                          |        |
| 2MWT, when applicable        |            |          |                         |                          |        |
| FVC (L and % of predicted)   |            |          |                         |                          |        |
| Electrocardiogram            |            |          |                         |                          |        |
| Hearing test (PTA)           |            |          |                         |                          |        |
| Psychotic events             |            |          |                         |                          |        |
| AEs/ADRs                     | X          | X        |                         |                          |        |
Health Assessment Questionnaires

| Questionnaire          | EQ-5D-5L | Zarit Burden Interview | CHAQ | Behavior checklists |
|------------------------|----------|------------------------|------|--------------------|
|                        | X        | X                      | X    | X                  |

Abbreviations: 3MSCT 3-min stair climbing test; 2MWT 2-min walk test; 6MWT 6-min walk test; ABCL Adult Behavior Checklist; AE adverse event; ADA alfa-immunoglobulin G antibody; ADR adverse drug reaction; ALP alkaline phosphatase; ALT alanine aminotransferase; ASR Adult Self-Report; AST aspartate transaminase; CBCL Child Behavior Checklist; CHAQ Childhood Health Assessment Questionnaire; EQ-5D-5L European Quality of Life, Five Dimension, Five-Level Scale; FVC forced vital capacity; Ig immunoglobulin; L liter; LDH lactate dehydrogenase; OABCL Older Adult Behavior Checklist; PTA pure tone audiometry; RMP risk management plan; VA velmanase alfa.

Note: Actual assessments performed per participating center Standard Operating Procedures.

1. Unscheduled follow-up visits can be performed at, but not limited to, 3 months after VA treatment start, or whenever deemed appropriate according to treating physician’s judgment for patients that start VA treatment within 1 year prior to Registry inclusion.

2. Additional follow-up visit after 6 months is highly recommended for patients that start VA treatment within 1 year prior to registry inclusion.

3. If not taken or collected at registry inclusion visit.

4. Patients’ retrospective data may be collected at the time of registry enrolment if available. Baseline visits are recommended to be repeated for those patients who will start VA therapy during the course of the study, before therapy is initiated.

5. Physical examination to collect vital signs, anthropometric measurements like height, weight, rate of growth, and the ability to perform the endurance test at the study visit.

6. If applicable, information regarding weekly VA therapy received by the patient need to be recorded within all the registry duration.

7. All assessments mentioned in the above table will be collected only if considered necessary and available as part of routine clinical practice by the treating physician and no additional tests specific to the registry will be done.

8. Standard test for hematology assessed by local laboratory if available per clinical practice of the site: Hemoglobin, hematocrit, platelet count, red blood cells, and white blood cells with differential count (all expressed in %, as well as in absolute numbers).

9. Standard test for hematology assessed by local laboratory if available per clinical practice: Biochemistry: serum electrolytes, creatinine, creatine-kinase, amylase, AST, ALT, ALP, albumin, bilirubin (total and direct), LDH.

10. The markers (oligosaccharides in serum, IgG, IgA, and ADA) will be evaluated through a central laboratory in European countries other than Germany. In Germany, marker testing will take place according to local routine clinical practice.

11. In patients 4 years and older, and when applicable according to the judgment of treating physician.

12. In patients under 4 years of age and when applicable according to the judgment of treating physician.

13. AEs/ADRs based on all risk categories associated with VA European RMP, including infusion related reactions and hypersensitivity (as identified risks), acute renal failure, loss of consciousness and medication errors (as potential risks). Data on pregnancy (including birth and newborn data) and lactation (as missing information) will be also collected if available.

14. One of the behavior checklists (CBCL pre-scholar/scholar, ABCL/ASR [self-reporting], OABCL) will be used to the applicable age and according to the judgment of treating physician.

Effectiveness variables

Efficacy outcomes to be assessed during routine clinical care are shown in Table 1. For patients under 4 years of age, a 3-min stair climb test (3MSCT) and 2-min walk test (2MWT) are suggested. The forced vital capacity (% volume predicted) is suggested for patients over 4 years of age, and according to the judgment of the treating physician. The proposed schedule of assessments is shown in Table 2, but, again, assessments will be made based on the participating centers’ Standard Operating Procedures.

A Global Treatment Response (GTR) to velmanase alfa will be evaluated in velmanase alfa-naive patients able to perform the functional tests after 3 years of treatment. The GTR will assess patients
in three clinical domains (pharmacodynamic, functional, and QoL) consisting of 1 or > 1 endpoint (Table 3). The pharmacodynamic domain comprises a measure of the accumulated substrate in alpha-mannosidase deficiency, the main pathogenic factor for disease manifestations; a decrease in oligosaccharides is a key biomarker of the pharmacologic effect of the ERT [3]. The second domain includes pulmonary function, endurance, and fine and gross motor proficiency, i.e., all the functional endpoints of the disease [3]. The QoL domain relates to patient-related outcomes of disease burden, disability, and pain [3]. A global response is defined as improvements exceeding the established minimal clinical important difference (MCID) (Table 3) in ≥ 1 endpoint in ≥ 2 of the domains [3]. The MCIDs are derived on the basis of those used in clinical conditions with the highest similarity to alpha-mannosidosis (proxy diseases) [9-12].

| Domain          | Endpoint       | Established MCID¹ |
|-----------------|----------------|-------------------|
| Pharmacodynamic | Serum-oligosaccharides | Last serum oligosaccharide value ≤ 4 µmol/L |
| Functional      | 3MSCT          | Improvement ≥ 7 steps/min [9] |
|                 | 6MWT           | Improvement ≥ 30 m [11] |
|                 | FVC%           | Improvement ≥ 10% [10] |
| QoL             | CHAQ DI        | Improvement ≤ − 0.130 [12] |
|                 | CHAQ Pain VAS  | Improvement ≤ − 0.246 [12] |

1MCID were derived from proxy diseases (3MSCT from MPS IV A clinical trials; 6MWT and FVC% from Pompe; CHAQ DI and CHAQ Pain VAS from juvenile arthritis).

Abbreviations: 3MSCT 3-min stair-climb test; 6MWT 6-min walk test; CHAQ DI Child Health Assessment Questionnaire Disability Index; CHAQ Pain VAS Child Health Assessment Questionnaire Pain Visual Analog Scale; FVC% forced volume capacity, percentage of predicted; GTR Global Treatment Response; MCID minimal clinically important difference; MPS IV A mucopolysaccharidosis type IV A; QoL quality of life.

Data management

Data sources will be the patient’s medical record and any other medical record of clinical findings accrued as part of routine care; retrospective data may be obtained from the patient’s medical record. All data related to the study will be entered in the eCRF and will be checked for accuracy and completeness as a component of ongoing study monitoring by an independent contract research organization (CRO) designated by Chiesi Farmaceutici S.p.A. Access to the eCRF will be granted to authorized personnel; sites will only be able to access data of patients enrolled at their site and the CRO will be entitled to access all data in a read-only mode.

Study size

As this is an observational study and there is no formal hypothesis testing, the size of the study was
conceptualized based on assumed different proportions of GTR in treatment-naïve patients who can perform functional tests after 3 years of treatment. Assuming at least 70 treated patients are enrolled, and assuming a GTR of at least 0.60 or more, the lower limit of the two-sided 95% confidence interval (Clopper-Pearson) is always above 45.0% (Table 4), which is considered a clinically relevant response. Thus, the efficacy analysis is based on a hypothetical treated population of at least 70 patients.

| Expected proportion | 95%CI lower limit | 95%CI upper limit | 95% actual width |
|---------------------|-------------------|-------------------|------------------|
| 0.60                | 0.476             | 0.715             | 0.239            |
| 0.65                | 0.527             | 0.760             | 0.234            |
| 0.70                | 0.579             | 0.804             | 0.225            |
| 0.75                | 0.632             | 0.846             | 0.214            |
| 0.80                | 0.687             | 0.886             | 0.199            |

Abbreviation: CI confidence interval.

Statistical analyses

Baseline demographic and disease characteristics will be presented by means of descriptive statistics and frequency distributions, as appropriate. Descriptive safety outcomes will be presented and summarized over time. For AEs, both the frequency of patients with an AE and the number of events will be presented by year from baseline. Safety variables will be presented based on person-years at risk. Effectiveness variables will be summarized by means of descriptive statistics or frequency of distribution, as appropriate, and all variables (actual values and change from baseline, if applicable) will be presented by time point. The effects of baseline characteristics on effectiveness will be evaluated by means of regression/logistic models. Covariates in the model will be age (<18 and ≥ 18 years), gender (male, female), sibships, genotype (Groups 1, 2, and 3, per Borgwardt et al.) [13], residual enzymatic activity (<10, 10 to <15, and ≥15 nmol/h/mg), and Childhood Health Assessment Questionnaire Disability Index (0–1, 1–2, and 2–3).

Provided that a sufficient number of nontreated patients with adequate data are enrolled, a comparison will be conducted between the velmanase alfa-treated and nontreated groups. Propensity score (PS) analysis will be used to compare GTRs after 3 years; the PS will be calculated as the predicted probability of response using logistic regression, with the same covariates as used for the baseline characteristics regression. Subgroup analyses may be performed depending on overall
sample size; results will be presented descriptively.

Discussion

SPARKLE is the first European-wide registry for alpha-mannosidosis that includes all patients, irrespective of treatment or study inclusion, who are willing to participate. The registry will expand the current understanding of alpha-mannosidosis by collecting natural history data, disease modifiers, and confounding factors in treated and untreated patients. Rare disease registries provide a valuable resource to enhance understanding of the diagnosis, heterogeneity, progression, burden of disease, and natural history of these conditions [14]. In addition, they help to characterize and describe patients, evaluate the long-term safety and effectiveness of available treatment options, and support measures to optimize patient care through recommendations for monitoring and development of treatment strategies.

SPARKLE is part of a growing number of rare disease registries, with over 750 listed in Europe as of May 2019 [15]. SPARKLE will contribute to the increasing database of information gathered from lysosomal storage disease registries, including those for Fabry disease, Pompe disease, Gaucher disease, and mucopolysaccharidoses [16, 17]. Importantly, SPARKLE is designed to provide a much-needed data set relating to alpha-mannosidosis and benefits from several strengths. The protocol adheres to the rare disease registry guidelines suggested by the International Rare Diseases Research Consortium [18] and recommendations of the European Union Committee of Experts on Rare Diseases [19]. In contrast to other registries that evaluate orphan medicinal products for the treatment of lysosomal storage disorders [20], the eligibility criteria for participation in SPARKLE are minimal, in order to allow the largest possible number of patients to participate. Methodologic rigor will be exercised to ensure the highest-quality data and data analysis. In addition, SPARKLE is the only alpha-mannosidosis registry, avoiding duplication of data collection; it is designed to collect both safety and efficacy data, as well as information on patient and disease characteristics; and it is not restricted to patients receiving a particular treatment, or a time when treatment is initiated. Some limitations need to be acknowledged. As information in the registry will be collected during routine clinical care, the assessments performed and data collected may vary from center to center,
as may the interpretation of data by the individual Investigators. In addition, bias may be introduced by patient self-selection into the study and it is unknown whether all patients with alpha-mannosidosis will be included as some may be treated in centers not participating in the registry. Thus, bias will be of unknown size and direction.

Conclusion
The SPARKLE study will provide real-world data on the long-term safety and effectiveness of velmanase alfa in European patients with alpha-mannosidosis during routine clinical care and will increase the understanding of the natural course, clinical manifestations, and progression of this ultra-rare disease in both treated and untreated patients.

Declarations

**Ethics approval and consent to participate**
Before the study commences, the protocol will be submitted to the Ethics Committee according to the requirements of each country. Informed consent will be obtained from each patient prior to the collection of any data.

**Consent for publication**
Not applicable.

**Availability of data and materials**
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Competing interests**

JBH received consulting fees and travel expenses from Chiesi Farmaceutici S.p.A., honoraria and travel expenses from Amicus and Shire. NG is a member of an advisory board and received consulting fees from BioMarin, Chiesi Farmaceutici S.p.A, Sanofi Genzyme, Shire, SOBI, and Ultragenyx Pharmaceutical Inc. FeCa and FeCe are employed at Chiesi Farmaceutici S.p.A. LB received consulting fees from Chiesi Farmaceutici S.p.A. AML received consulting fees from Alexion, BioMarin, Chiesi Farmaceutici S.p.A., Sanofi Genzyme, and Shire. MG-C and AT-S were members of an advisory board for Chiesi Farmaceutici S.p.A. NMM is a consultant for BioMarin, Sanofi Genzyme, Lysogene, Shire, and...
SOBI, has received grants/research support from Amicus, BioMarin, Sanofi Genzyme, and Shire, and has received honoraria and/or travel grants from Actelion, Amicus, BioMarin, Chiesi Farmaceutici S.p.A., Sanofi Genzyme, and Shire.

**Funding**

SPARKLE was sponsored by Chiesi Farmaceutici S.p.A. The sponsor was involved in the protocol development and regulatory and ethics approvals. Chiesi Farmaceutici S.p.A. funded third-party writing assistance for the current manuscript, provided by Parexel International.

**Authors’ contributions**

All authors made significant contribution to the development of the protocol, were major contributors in drafting the manuscript, and read and approved the final manuscript.

**Abbreviations**

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| 2MWT         | 2-min walk test                                  |
| 3MSCT        | 3-min stair climbing test                        |
| 6MWT         | 6-min walk test                                  |
| ABCL         | Adult Behavior Checklist                         |
| ADA          | alfa-immunoglobulin G antibody                   |
| ADR          | adverse drug reaction                            |
| AE           | adverse event                                   |
| ALP          | alkaline phosphatase                             |
| ALT          | alanine aminotransferase                         |
| ASR          | Adult Self-Report                                |
| AST          | aspartate transaminase                           |
| CBCL         | Child Behavior Checklist                         |
| CHAQ         | Childhood Health Assessment Questionnaire        |
| CHAQ DI      | Child Health Assessment Questionnaire Disability Index |
| CHAQ Pain VAS| Child Health Assessment Questionnaire Pain Visual Analog Scale |
| CI           | confidence interval                              |
CRO  clinical research organization
DBP  diastolic blood pressure
eCRF  electronic case report form
EQ-5D-5L  European Quality of Life, Five Dimension, Five Level Scale
ERT  enzyme replacement therapy
FVC  forced vital capacity
FVC%  forced vital capacity percent of predicted
GTR  Global Treatment Response
Ig  immunoglobulin
L  liter
LDH  lactate dehydrogenase
MCID  minimal clinically important difference
MPS IV A  mucopolysaccharidosis type IV A
OABCL  Older Adult Behavior Checklist
PS  propensity score
PTA  pure tone audiometry
QoL  quality of life
RCT  randomized controlled trial
RMP  risk management plan
SBP  systolic blood pressure
VA  velmanase alfa

References
1. Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;321.
2. OMIM®. 2017 Available from: https://www.omim.org/entry/248500.
3. Harmatz P, Cattaneo F, Ardigò D, Geraci S, Hennermann JB, Guffon N, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-
mannosidosis. Mol Genet Metab. 2018;124(2):152-60.

4. Beck M, Olsen KJ, Wraith JE, Zeman J, Michalski JC, Saftig P, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis. 2013;888.

5. Lund AM, Borgwardt L, Cattaneo F, Ardigò D, Geraci S, Gil-Campos M, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225-33.

6. Lamzede® SmPC. 2018 Available from: https://www.ema.europa.eu/en/documents/product-information/lamzede-epar-product-information_en.pdf.

7. Hennermann J, Guffon N, Cattaneo F, Pirondi S, Borgwardt L, Lund AM, et al. The SPARKLE study: shedding light on alpha-mannosidosis. Poster presented at the 15th Annual WORLD Symposium, February 4-8, 2019, Orlando, FL, USA Poster number:156. 2019.

8. Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, et al. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215-23.

9. CADTH Common Drug Review. 2015 Available from: https://www.cadth.ca/elosulfase-alfa-vimizim.

10. Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum. 2001;44(8):1768-74.

11. Dhanani S, Quenneville J, Perron M, Abdolell M, Feldman BM. Minimal difference in pain associated with change in quality of life in children with rheumatic disease.
12. Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis. 2013;8160.

13. Borgwardt L, Stensland HM, Olsen KJ, Wibrand F, Klenow HB, Beck M, et al. Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation. Orphanet J Rare Dis. 2015;1070.

14. Gliklich RE, Dreyer NA, Leavy MB, Christian JB. Rare Disease Registries. In: Gliklich RE, Dreyer NA, Leavy MB, Christian JB, ed. eds. 21st Century Patient Registries: Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition, Addendum. Agency for Healthcare Research and Quality (US): Rockville, MD, 2018.

15. Orphanet. 2019 Available from: https://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf.

16. Orphanet. 2019 Available from: https://www.orpha.net/consor/cgi-bin/ResearchTrials_RegistriesMaterials.php?lng=EN.

17. Network RDCR. 2019 Available from: https://www.rarediseasesnetwork.org/ldn.

18. International Rare Diseases Research Consortium. 2013 Available from: http://www.irdirc.org/wp-content/uploads/2017/10/IRDiRC_policies_24MayApr2013.pdf.

19. EUCERD and EPIRARE. 2013 Available from: http://www.eucerd.eu/wp-content/uploads/2013/06/WP8WorkshopEJAEPICARE.pdf.

20. Hollak CE, Aerts JM, Ayme S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis. 2011;616.

Figures
Study design. Abbreviation: VA velmanase alfa. aIf applicable in accordance with routine clinical practice, unscheduled follow-up visits can be performed at, but not limited to, 3 months after VA treatment start, or whenever deem appropriate according to clinician judgment for patients who start VA treatment within 1 year prior to registry inclusion. bIf a patient is transferred to another continuing care site during the 15-year observational period, the new treating site will be formally involved in the registry following a request of authorization submitted to the relevant Ethics Committee and Regulatory Authority to complete the 15-year observational period. cPatients can start VA treatment at any time during the course of their participation in the registry; if applicable in accordance with routine clinical practice the baseline visit should be repeated before administration of VA and unscheduled visits recommended as reported in the schema above.